, ,

Several studies have assessed either vaginal progesterone or intramuscular 17α-hydroxyprogesterone caproate for the prevention of preterm birth in asymptomatic women with singleton pregnancy at high risk of preterm birth. An individual patient data meta-analysis of women with a short cervix showed that vaginal progesterone reduced the risk of preterm birth before 33 weeks (relative risk [RR] 0·58, 95% CI 0·42–0·80) and reduced a composite of neonatal mortality and morbidity (RR 0·57, 0·40–0·81).1 Although there is debate whether vaginal and intramuscular therapies have similar mechanisms or efficacy,………continue reading